Marcus Corporation reported 43% year-over-year consolidated adjusted EBITDA growth to $46.2 million in Q2 2026, with theatre EBITDA rising 37%. Premium large-format screens at 84% of locations and hotel division diversification support strong operating leverage and earnings growth.
Strong comparable admissions growth (23.6% YOY in Q1 2026), successful premium pricing strategy (12.7% ticket price increase), declining operating expenses, solid cash position ($194M), and positive technical indicators (Golden Cross, bullish MACD crossover) support continued upward momentum.
Articles that tag MCS but are mainly about other companies.
Zacks Rank #1 (Strong Buy) with strong movie attendance, higher ticket prices, and healthy leisure demand in hotels/resorts. Expected 8.3% sales growth and exceptional 652.9% earnings growth in 2026. Stock gained 85% in the past year.
Zacks Rank #1 (Strong Buy) with 85% year-over-year share surge. Benefiting from strong movie attendance, higher ticket prices, and healthy leisure demand. Expected 8.3% sales and 652.9% earnings growth in 2026.
Closed down 1.83%, showing similar sector-wide pressure affecting theatrical exhibition companies.
Referenced as another competitor with more reasonable valuation than AMC, used as a comparative baseline for appropriate theater stock valuations.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
